

## PRESS RELEASE

### **Dotarem® (gadoterate meglumine) Injection Now Offered Via Novation, USA's Leading Group Purchasing Organization**

Villepinte, 12 November 2013

Guerbet LLC (USA) announced that Novation, the leading healthcare supply chain expertise, analytics and contracting company in the US, has awarded a new agreement for Dotarem® (gadoterate meglumine) Injection.

Dotarem® is a gadolinium-based contrast agent indicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associated tissues in adult and pediatric patients (2 years of age and older) to detect and visualize areas with disruption of the blood brain barrier and/or abnormal vascularity.

With over 42 million doses administered to patients outside the United States <sup>[1]</sup>, Dotarem® has been commercialized worldwide since 1989. It is the only macrocyclic and ionic gadolinium-based contrast agent. The recommended dose is 0.2 mL/kg (0.1 mmol/kg) body weight.

The agreement, effective November 1, 2013, was awarded through Novation's competitive *Innovative Technology* program, which seeks to identify and contract for innovative products that are used in clinical care and offer an incremental benefit to the care and safety of a patient and health worker.

"We are very pleased to have been selected through Novation's new technology process and are eager to provide the broad range of members served by Novation an alternative like Dotarem®, only a few months after approval by the FDA and its commercial launch" said Massimo Carrara, General Manager, Guerbet US.

---

<sup>[1]</sup> Data as of November 1, 2013

## **Important Safety Information**

In compliance with recommendations issued by national, European (EMA) and US (FDA) drug safety agencies, product leaflets and prescribing information for gadolinium-based contrast agents contain information on the risks of nephrogenic systemic fibrosis (NSF).

For further information on Dotarem®, and notably full safety information, please refer to the summary of product characteristics in force in each country.

## **About Dotarem®**

More than 42 million doses of Dotarem® have been administered to patients in over 70 countries in Europe, Asia, the Middle East and Latin America. The authorized indications for Dotarem® may vary from country to country. Dotarem® is the leading MRI contrast agent in Europe with a 47% market share in 2012 (MRI, in volume. ECMIG 2011).

## **About Guerbet**

A pioneer in the field of contrast agents with more than 80 years of experience, Guerbet is the only pharmaceutical group fully dedicated to medical imaging worldwide. As such it has a complete offering of contrast products for X-ray and MRI and for interventional radiology, along with a range of injectors and related medical equipment to provide improved diagnosis and treatment of patients.

To promote the discovery of new products and assure future growth, Guerbet devotes significant resources to research and development every year (approximately 10% of sales). Guerbet (GBT) is listed on NYSE Euronext Paris (Eurolist Segment B – Mid Caps) and had sales of €403 million in 2012 with a total workforce of 1,400 employees, of which 1,000 are in France.

## **About Novation**

Founded in 1998, Novation is the leading health care supply chain expertise, analytics and contracting company for the more than 65,000 members and affiliates of VHA Inc. and UHC, two national health care alliances, Children's Hospital Association, an alliance of the nation's leading pediatric facilities, and Provista, LLC.

Novation provides alliance members with sourcing services, as well as information and data services. Based in Irving, Texas, Novation develops and manages competitive contracts with more than 600 suppliers. VHA, UHC, and Provista members used Novation contracts to purchase approximately \$43 billion in 2012.

To learn more about Novation, please visit [www.novationco.com](http://www.novationco.com)

## **France Press Contact**

**Anne-Laure Delasalle, Communications Director**

Tel.: + 33 (0)1 45 91 50 03

[anne-laure.delasalle@guerbet-group.com](mailto:anne-laure.delasalle@guerbet-group.com)

## **USA Press Contact**

**Ted Deutsch**

Tel.: + 001 (609) 578-8765

[ted@taftandpartners.com](mailto:ted@taftandpartners.com)

*This press release may contain forward-looking statements based on current assumptions and forecasts made by Guerbet Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performances of the company and the estimates given here. These factors include those discussed in Guerbet's public reports which are available on the Guerbet website at [www.guerbet.com](http://www.guerbet.com). The company assumes no liability whatsoever to update these forward-looking-statements or to conform them to future events or developments.*

*Dotarem<sup>®</sup> is a trade mark registered by Guerbet*

que déposée par Guerbet.

*This press release may contain forward-looking statements based on current assumptions and forecasts made by Guerbet Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performances of the company and the estimates given here. These factors include those discussed in Guerbet's public reports which are available on the Guerbet website at [www.guerbet.com](http://www.guerbet.com). The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.*

*Dotarem<sup>®</sup> is registered in U.S. Patent and Trademark Office by Guerbet and is available by prescription only.*